Developing a predictive model for disease status in breast cancer patients using Th1 and Th2 serum cytokine profiles

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10078-10078 ◽  
Author(s):  
S. Khoo ◽  
T. Kao ◽  
Z. A. Dehqanzada ◽  
C. E. Storrer ◽  
K. A. Harris ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Predictive Value ◽  
Small Sample ◽  
Nodal Status ◽  
Outcome Variable ◽  
Breast Cancer Patients ◽  
Serum Cytokine ◽  
Gm Csf ◽  
Cytokine Levels ◽  
Potential Biomarkers

10078 Background: Using the Luminex multiplex assay, we have reported significant correlations between serum levels of MCP-1, eotaxin, and IL-6 and disease characteristics in breast cancer (BCa) patients. We now examine the potential of utilizing a general cytokine profile to develop a statistical model to predict certain disease states in these patients. Methods: Sera from 36 BCa patients (24 node-negative, 12 node-positive, 12 normals) were analyzed using the Luminex assay for levels of 21 cytokines (IL-1α, 1b, 2, 4, 5, 6, 8, 10, 12, 13, 15, 17, IFN-γ, G-CSF, GM-CSF, TNF-α, IP-10, MIP-1α, RANTES, MCP-1, eotaxin). Logistic regression models were used to assess if a binary outcome variable (Y) can be predicted by using serum cytokine levels (X). The area under a receiver operating characteristic (ROC) curve (c) was used to assess the potential utility of a biomarker. The larger the value of c, the better the biomarker. Results: MCP-1 was found to be a possible predictor of the presence of BCa while other potential biomarkers were IL-13, MIP-1α and eotaxin. The higher the MCP-1 level, the greater the likelihood that the patient would have BCa. Similar relationships applied to the other potential biomarkers. Among BCa patients, GM-CSF seemed to be a good predictor of nodal status with lower levels of GM-CSF predicting positive nodes. Other potential biomarkers with a similar expression pattern for nodal status were MCP-1, IL-6 and IL-5. Due to small sample sizes, we were unable to examine a potential “panel” of cytokines to develop a prognostic algorithm based on serum analysis. Conclusions: MCP-1, which was previously shown to be elevated in BCa, may also have some predictive value linking the presence of disease and disease severity as measured by nodal status. Other prominent cytokines from earlier studies (MIP-1α, eotaxin, IL-6) also displayed some possible predictive value. Our results warrant studying a larger population in order to establish a unified prognostic formula for BCa based on serum cytokine levels. [Table: see text] No significant financial relationships to disclose.

scholarly journals Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab

2018 ◽  
Vol 7 (11) ◽  
pp. e1457598 ◽  
Author(s):  
Shakila Jabeen ◽  
Manuela Zucknick ◽  
Marianne Nome ◽  
Ruth Dannenfelser ◽  
Thomas Fleischer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Neoadjuvant Treatment ◽  
Breast Cancer Patients ◽  
Serum Cytokine ◽  
Cytokine Levels

scholarly journals Onset of fatigue in breast cancer patients: correlation with serum cytokine levels, and blood cell counts

2016 ◽  
Vol 27 ◽  
pp. iv122
Author(s):  
M. Santoro ◽  
E. Iuliano ◽  
M. Luci ◽  
A. Perricelli ◽  
A. Pomillo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Blood Cell ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Serum Cytokine ◽  
Cell Counts ◽  
Blood Cell Counts ◽  
Cytokine Levels

Serum cytokine levels and the expression of estrogen and progesterone receptors in breast cancer patients

2006 ◽  
Vol 44 (9) ◽  
Author(s):  
Malgorzata Fuksiewicz ◽  
Janina Kaminska ◽  
Beata Kotowicz ◽  
Maria Kowalska ◽  
Maryna Rubach ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Progesterone Receptors ◽  
Breast Cancer Patients ◽  
Serum Cytokine ◽  
Estrogen And Progesterone Receptors ◽  
Cytokine Levels

AbstractClin Chem Lab Med 2006;44:1092–7.

scholarly journals PITX2 DNA-Methylation: Predictive versus Prognostic Value for Anthracycline-Based Chemotherapy in Triple-Negative Breast Cancer Patients

Breast Care ◽  
2020 ◽  
pp. 1-9
Author(s):  
Rudolf Napieralski ◽  
Gabriele Schricker ◽  
Gert Auer ◽  
Michaela Aubele ◽  
Jonathan Perkins ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Methylation ◽  
Cancer Patients ◽  
Triple Negative Breast Cancer ◽  
Predictive Value ◽  
Untreated Patient ◽  
Triple Negative ◽  
Statistical Significance ◽  
Breast Cancer Patients ◽  
The Impact

<b><i>Background:</i></b> PITX2 DNA methylation has been shown to predict outcomes in high-risk breast cancer patients after anthracycline-based chemotherapy. To determine its prognostic versus predictive value, the impact of PITX2 DNA methylation on outcomes was studied in an untreated cohort vs. an anthracycline-treated triple-negative breast cancer (TNBC) cohort. <b><i>Material and Methods:</i></b> The percent DNA methylation ratio (PMR) of paired-like homeodomain transcription factor 2 (PITX2) was determined by a validated methylation-specific real-time PCR test. Patient samples of routinely collected archived formalin-fixed paraffin-embedded (FFPE) tissue and clinical data from 144 TNBC patients of 2 independent cohorts (i.e., 66 untreated patients and 78 patients treated with anthracycline-based chemotherapy) were analyzed. <b><i>Results:</i></b> The risk of 5- and 10-year overall survival (OS) increased continuously with rising PITX2 DNA methylation in the anthracycline-treated population, but it increased only slightly during 10-year follow-up time in the untreated patient population. PITX2 DNA methylation with a PMR cutoff of 2 did not show significance for poor vs. good outcomes (OS) in the untreated patient cohort (HR = 1.55; <i>p</i> = 0.259). In contrast, the PITX2 PMR cutoff of 2 identified patients with poor (PMR &#x3e;2) vs. good (PMR ≤2) outcomes (OS) with statistical significance in the anthracycline-treated cohort (HR = 3.96; <i>p</i> = 0.011). The results in the subgroup of patients who did receive anthracyclines only (no taxanes) confirmed this finding (HR = 5.71; <i>p</i> = 0.014). <b><i>Conclusion:</i></b> In this hypothesis-generating study PITX2 DNA methylation demonstrated predominantly predictive value in anthracycline treatment in TNBC patients. The risk of poor outcome (OS) correlates with increasing PITX2 DNA methylation.

scholarly journals Abnormal Long Non-Coding RNAs Expression Patterns Have the Potential Ability for Predicting Survival and Treatment Response in Breast Cancer

Genes ◽  
2021 ◽  
Vol 12 (7) ◽  
pp. 996
Author(s):  
Ana Carolina Pavanelli ◽  
Flavia Rotea Mangone ◽  
Luciana R. C. Barros ◽  
Juliana Machado-Rugolo ◽  
Vera L. Capelozzi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Predictive Value ◽  
Expression Patterns ◽  
Survival Rates ◽  
In Silico Analysis ◽  
Cancer Prognosis ◽  
Response To Treatment ◽  
Breast Cancer Patients ◽  
Non Coding Rnas

Abnormal long non-coding RNAs (lncRNAs) expression has been documented to have oncogene or tumor suppressor functions in the development and progression of cancer, emerging as promising independent biomarkers for molecular cancer stratification and patients’ prognosis. Examining the relationship between lncRNAs and the survival rates in malignancies creates new scenarios for precision medicine and targeted therapy. Breast cancer (BRCA) is a heterogeneous malignancy. Despite advances in its molecular classification, there are still gaps to explain in its multifaceted presentations and a substantial lack of biomarkers that can better predict patients’ prognosis in response to different therapeutic strategies. Here, we performed a re-analysis of gene expression data generated using cDNA microarrays in a previous study of our group, aiming to identify differentially expressed lncRNAs (DELncRNAs) with a potential predictive value for response to treatment with taxanes in breast cancer patients. Results revealed 157 DELncRNAs (90 up- and 67 down-regulated). We validated these new biomarkers as having prognostic and predictive value for breast cancer using in silico analysis in public databases. Data from TCGA showed that compared to normal tissue, MIAT was up-regulated, while KCNQ1OT1, LOC100270804, and FLJ10038 were down-regulated in breast tumor tissues. KCNQ1OT1, LOC100270804, and FLJ10038 median levels were found to be significantly higher in the luminal subtype. The ROC plotter platform results showed that reduced expression of these three DElncRNAs was associated with breast cancer patients who did not respond to taxane treatment. Kaplan–Meier survival analysis revealed that a lower expression of the selected lncRNAs was significantly associated with worse relapse-free survival (RFS) in breast cancer patients. Further validation of the expression of these DELncRNAs might be helpful to better tailor breast cancer prognosis and treatment.

scholarly journals CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience

2021 ◽  
Vol 9 (2) ◽  
pp. 42
Author(s):  
Angeliki Andrikopoulou ◽  
Oraianthi Fiste ◽  
Kleoniki Apostolidou ◽  
Efthymia Skafida ◽  
Christos Markellos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Small Sample Size ◽  
Small Sample ◽  
Musculoskeletal Symptoms ◽  
Hematological Toxicity ◽  
Breast Cancer Patients ◽  
Single Institution ◽  
Duration Of Treatment ◽  
Positive Breast Cancer

Background: Aromatase inhibitors (AIs) are associated with musculoskeletal pain in one third (20–47%) of breast cancer patients. Recently, CDK4/6 inhibitors have emerged as a new therapeutic approach in hormone receptor (HR)-positive breast cancer. While hematological and gastrointestinal toxicities are frequently reported during treatment with CDK4/6 inhibitors, musculoskeletal symptoms are less commonly encountered. Methods: Herein, we present a retrospective study of 47 breast cancer patients who received CDK4/6 inhibitors along with endocrine therapy in our department between 01/01/2018 and 01/09/2020. Results: Median age at diagnosis was 58 years (29–81). Median duration of treatment was 8.76 months (SD: 7.68; 0.47–30.13 months). Median PFS was 24.33 months (95% CI; 1.71–46.96). Overall, toxicity was reported in 61.7% of the cases (29/47). Arthralgia was reported in 6.4% (3/47) of the patients. Hematological toxicity was reported in 51.1% (24/47) of the patients. Neutropenia was the main hematological toxicity observed (86.8%; 22/47) along with anemia (4.3%; 2/47), thrombocytopenia (2.1%; 1/47), and leukopenia (4.2%; 1/24). Conclusions: Though our data reflect a small sample size, we report a reduced arthralgia rate (6.4%) during treatment with CDK4/6 inhibitors compared with that reported in studies of AIs (20–47%).

Sign in / Sign up

Export Citation Format

Share Document